Literature DB >> 10027853

Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.

P Salvati1, R Maj, C Caccia, M A Cervini, M G Fornaretto, E Lamberti, P Pevarello, G A Skeen, H S White, H H Wolf, L Faravelli, M Mazzanti, E Mancinelli, M Varasi, R G Fariello.   

Abstract

PNU-151774E [(S)-(+)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide methanesulfonate], a new anticonvulsant that displays a wide therapeutic window, has a potency comparable or superior to that of most classic anticonvulsants. PNU-151774E is chemically unrelated to current antiepileptics. In animal seizure models it possesses a broad spectrum of action. In the present study, the action mechanism of PNU-151774E has been investigated using electrophysiological and biochemical assays. Binding studies performed with rat brain membranes show that PNU-151774E has high affinity for binding site 2 of the sodium channel receptor, which is greater than that of phenytoin or lamotrigine (IC50, 8 microM versus 47 and 185 microM, respectively). PNU-151774E reduces sustained repetitive firing in a use-dependent manner without modifying the first action potential in hippocampal cultured neurons. In the same preparation PNU-151774E inhibits tetrodotoxin-sensitive fast sodium currents and high voltage-activated calcium currents under voltage-clamp conditions. These electrophysiological activities of PNU-151774E correlate with its ability to inhibit veratrine and KCl-induced glutamate release in rat hippocampal slices (IC50, 56.4 and 185.5 microM, respectively) and calcium inward currents in mouse cortical neurons. On the other hand, PNU-151774E does not affect whole-cell gamma-aminobutryic acid- and glutamate-induced currents in cultured mouse cortical neurons. These results suggest that PNU-151774E exerts its anticonvulsant activity, at least in part, through inhibition of sodium and calcium channels, stabilizing neuronal membrane excitability and inhibiting transmitter release. The possible relevance of these pharmacological properties to its antiepileptic potential is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027853

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Safinamide.

Authors:  Ruggero G Fariello
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 2.  Formulary Drug Review: Safinamide.

Authors:  Danial E Baker; Anne P Kim
Journal:  Hosp Pharm       Date:  2017-08-18

3.  Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.

Authors:  Yuying Wang; Sarah M Wilson; Joel M Brittain; Matthew S Ripsch; Christophe Salomé; Ki Duk Park; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

4.  Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

5.  Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.

Authors:  Andrea Francesco Daniele Di Stefano; Antonio Rusca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

6.  Real life evaluation of safinamide effectiveness in Parkinson's disease.

Authors:  Francesca Mancini; Alessio Di Fonzo; Giulia Lazzeri; Linda Borellini; Vincenzo Silani; Marco Lacerenza; Cristoforo Comi
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307

7.  Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.

Authors:  Mario Giorgio Rizzone; Francesca Mancini; Carlo Alberto Artusi; Roberta Balestrino; Salvatore Bonvegna; Margherita Fabbri; Gabriele Imbalzano; Elisa Montanaro; Alberto Romagnolo; Maurizio Zibetti; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2022-01-04       Impact factor: 3.830

8.  Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide.

Authors:  Ki Duk Park; Xiao-Fang Yang; Erik T Dustrude; Yuying Wang; Matthew S Ripsch; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2014-12-09       Impact factor: 4.418

9.  Substituted N-(biphenyl-4'-yl)methyl (R)-2-acetamido-3-methoxypropionamides: potent anticonvulsants that affect frequency (use) dependence and slow inactivation of sodium channels.

Authors:  Hyosung Lee; Ki Duk Park; Robert Torregrosa; Xiao-Fang Yang; Erik T Dustrude; Yuying Wang; Sarah M Wilson; Cindy Barbosa; Yucheng Xiao; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  J Med Chem       Date:  2014-07-15       Impact factor: 7.446

Review 10.  Investigational agents in the treatment of Parkinson's disease: focus on safinamide.

Authors:  Naveed M Malek; Donald G Grosset
Journal:  J Exp Pharmacol       Date:  2012-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.